OrganiGram Holdings (TSE:OGI) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Organigram Holdings Inc. has announced promising preliminary results from a clinical study on its new FAST™ nanoemulsion technology, which offers a faster onset and improved bioavailability of cannabinoids for ingestible products. The technology is set to enhance Organigram’s product line, providing consumers with more control over their dosage experience. Final results of the study, which could significantly impact the adult-use cannabis market, are expected to be published later this year.
For further insights into TSE:OGI stock, check out TipRanks’ Stock Analysis page.
